Consequences of using different methods to assess cardiovascular risk in primary care

被引:25
作者
Fornasini, M
Brotons, C
Sellarès, J
Martinez, M
Galán, ML
Sáenz, I
da Pena, JM
机构
[1] Sardenya Primary Hlth Ctr, Unit Res, Barcelona 08025, Spain
[2] Univ San Francisco Quito, Quito, Ecuador
关键词
cardiovascular risk assessment; lipid lowering drugs; primary care;
D O I
10.1093/fampra/cmi092
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background. There are two promising methods to assess cardiovascular risk: the Adult Treatment Panel III (ATPIII) and the Systematic Coronary Risk Evaluation (SCORE). The ATPIII calculates the 10-year risk of coronary events based on an adaptation of the original Framingham function. The SCORE chart is based on European studies and measures the absolute risk of cardiovascular mortality in the next 10 years. Objective. To evaluate the clinical consequences of using different methods to calculate cardiovascular risk and different primary prevention guidelines. Methods. A cross sectional study of 914 dyslipidemic patients from three primary health centres from Catalonia, Spain, was conducted. Outcome variables were the risk level according to the different equations (classical Framingham table by Anderson, ATPIII adapted Framingham table, and SCORE system), and candidates for lipid lowering treatment according to European and ATPIII guidelines. Results. The proportion of high-risk patients according to the three equations and excluding diabetic patients was 13.5%, 11.4% and 7.1%, respectively, and 20.2%, 25.7% and 29.2%, respectively when including diabetic patients. The prevalence of candidates for lipid lowering treatment according to European guidelines and ATPIII guidelines were 28.8% and 39.3%, respectively. A 49% disagreement with a Kappa of -0.1, and a 37% disagreement with a Kappa of 0.08 were observed when comparing candidates identified for lipid lowering treatment and patients actually receiving that treatment, according to ATPIII and SCORE guidelines, respectively. Conclusion. Our results suggest important clinical and economic consequences when comparing European guidelines or ATPIII guidelines for the treatment of dyslipidemic patients in general practice.
引用
收藏
页码:28 / 33
页数:6
相关论文
共 13 条
  • [1] CARDIOVASCULAR-DISEASE RISK PROFILES
    ANDERSON, KM
    ODELL, PM
    WILSON, PWF
    KANNEL, WB
    [J]. AMERICAN HEART JOURNAL, 1991, 121 (01) : 293 - 298
  • [2] The Framingham prediction rule is not valid in a European population of treated hypertensive patients
    Bastuji-Garin, S
    Deverly, A
    Moyse, D
    Castaigne, A
    Mancia, G
    de Leeuw, PW
    Ruilope, LM
    Rosenthal, T
    Chatellier, G
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 (10) : 1973 - 1980
  • [3] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [4] Estimation of ten-year risk of fatal cardiovascular disease in Europe:: the SCORE project
    Conroy, RM
    Pyörälä, K
    Fitzgerald, AP
    Sans, S
    Menotti, A
    De Backer, G
    De Bacquer, D
    Ducimetière, P
    Jousilahti, P
    Keil, U
    Njolstad, I
    Oganov, RG
    Thomsen, T
    Tunstall-Pedoe, H
    Tverdal, A
    Wedel, H
    Whincup, P
    Wilhelmsen, L
    Graham, IM
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (11) : 987 - 1003
  • [5] Validation of the Framingham Coronary Heart Disease prediction scores - Results of a multiple ethnic groups investigation
    D'Agostino, RB
    Grundy, S
    Sullivan, LM
    Wilson, P
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (02): : 180 - 187
  • [6] European guidelines on cardiovascular disease prevention in clinical practice -: Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice
    De Backer, G
    Ambrosioni, E
    Borch-Johnsen, K
    Brotons, C
    Cifkova, R
    Dallongeville, J
    Ebrahim, S
    Faergeman, O
    Graham, I
    Mancia, G
    Cats, VM
    Orth-Gomér, K
    Perk, J
    Pyörälä, K
    Rodicio, JL
    Sans, S
    Sansoy, V
    Sechtem, U
    Silber, S
    Thomsen, T
    Wood, D
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (17) : 1601 - 1610
  • [7] Framingham risk function overestimates risk of coronary heart disease in men and women from Germany -: results from the MONICA Augsburg and the PROCAM cohorts
    Hense, HW
    Schulte, H
    Löwel, H
    Assmann, G
    Keil, U
    [J]. EUROPEAN HEART JOURNAL, 2003, 24 (10) : 937 - 945
  • [8] MANAGEMENT OF RAISED BLOOD-PRESSURE IN NEW-ZEALAND - A DISCUSSION DOCUMENT
    JACKSON, R
    BARHAM, P
    BILLS, J
    BIRCH, T
    MCLENNAN, L
    MACMAHON, S
    MALING, T
    [J]. BRITISH MEDICAL JOURNAL, 1993, 307 (6896) : 107 - 110
  • [9] Comparative accuracy of cardiovascular risk prediction methods in primary care patients
    Jones, AF
    Walker, J
    Jewkes, C
    Game, FL
    Bartlett, WA
    Marshall, T
    Bayly, GR
    [J]. HEART, 2001, 85 (01) : 37 - 43
  • [10] An adaptation of the Framingham coronary heart disease risk function to European Mediterranean areas
    Marrugat, J
    D'Agostino, R
    Sullivan, L
    Elosua, R
    Wilson, P
    Ordovas, J
    Solanas, P
    Cordón, F
    Ramos, R
    Sala, J
    Masiá, R
    Kannel, WB
    [J]. JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH, 2003, 57 (08) : 634 - 638